Literature DB >> 3581095

Selection factors in clinical trials: results from the Community Clinical Oncology Program Physician's Patient Log.

C P Hunter, R W Frelick, A R Feldman, A R Bavier, W H Dunlap, L Ford, D Henson, D Macfarlane, C R Smart, R Yancik.   

Abstract

Between August 1984 and November 1985, data concerning 44,156 newly diagnosed cancer patients were entered in the Community Clinical Oncology Program Physician's Patient Log. Forty percent (17,773 patients) had a National Cancer Institute-approved protocol available for site and stage of disease. Fifty-six percent of patients with a protocol available were clinically eligible and 19% were entered on protocol. Thus, one-third of clinically eligible patients were entered in the study. Age was a major factor influencing eligibility and entry on study. Eighty percent of patients less than 25 years of age with a protocol available were clinically eligible for clinical trials participation, and 58% were placed on protocol. Patients greater than or equal to 65 years of age with a protocol available were less likely to be clinically eligible (48%) or placed on study (14%). A physician's preference for an alternate treatment and patient refusal for protocol treatment were also important reasons that clinically eligible patients were not registered on protocol. Selection for clinical trials participation affects the characteristics of patients under study and may have an impact on the ability to generalize the results of clinical trials.

Entities:  

Mesh:

Year:  1987        PMID: 3581095

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  23 in total

Review 1.  Increasing participation of minorities in cancer clinical trials: summary of the "Moving Beyond the Barriers" Conference in North Carolina.

Authors:  Nancy Stark; Electra Paskett; Ronny Bell; M Robert Cooper; Elizabeth Walker; Alma Wilson; Cathy Tatum
Journal:  J Natl Med Assoc       Date:  2002-01       Impact factor: 1.798

2.  Sick population--treated population: the need for a better definition. The VALIDATA Group.

Authors:  J P Collet; J P Boissel
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Designing clinical protocols for optimal use: measuring attributes of treatment and cancer control trials.

Authors:  J E Veney; W P Kory; J M Barnsley; A D Kaluzny
Journal:  J Med Syst       Date:  1991-12       Impact factor: 4.460

4.  Evaluating productivity in clinical research programs: the National Cancer Institute's (NCI) Community Clinical Oncology Program (CCOP).

Authors:  D M Hynes; C P McLaughlin; A D Kaluzny; L P Ford; E Sondik
Journal:  J Med Syst       Date:  1992-12       Impact factor: 4.460

5.  Attitude of African-Americans regarding prostate cancer clinical trials.

Authors:  S B Robinson; M Ashley; M A Haynes
Journal:  J Community Health       Date:  1996-04

6.  The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies.

Authors:  Joseph M Unger; Elise Cook; Eric Tai; Archie Bleyer
Journal:  Am Soc Clin Oncol Educ Book       Date:  2016

7.  Improving clinical trial accrual by streamlining the referral process.

Authors:  Lawrence B Afrin; James C Oates; Diane L Kamen
Journal:  Int J Med Inform       Date:  2014-09-16       Impact factor: 4.046

8.  Recruitment of Ischemic Stroke Patients in Clinical trials in General Practice and Implications for Generalizability of Results.

Authors:  M Fareed; K Suri; Adnan I Qureshi
Journal:  J Vasc Interv Neurol       Date:  2012-06

9.  Hospitalization costs of total knee arthroplasty with a continuous femoral nerve block provided only in the hospital versus on an ambulatory basis: a retrospective, case-control, cost-minimization analysis.

Authors:  Brian M Ilfeld; Edward R Mariano; Brian A Williams; Jennifer N Woodard; Alex Macario
Journal:  Reg Anesth Pain Med       Date:  2007 Jan-Feb       Impact factor: 6.288

10.  Barriers to black women's participation in cancer clinical trials.

Authors:  C P Mouton; S Harris; S Rovi; P Solorzano; M S Johnson
Journal:  J Natl Med Assoc       Date:  1997-11       Impact factor: 1.798

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.